BACKGROUND: The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient's sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection. METHODS: Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment. RESULTS: Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment. CONCLUSION: We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure. TRIAL REGISTRATION: Registration is not required for observational studies. FUNDING: This study was funded by Emory University, the NIH, and the Yerkes National Primate Center.
BACKGROUND: The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient's sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection. METHODS: Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment. RESULTS: Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment. CONCLUSION: We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure. TRIAL REGISTRATION: Registration is not required for observational studies. FUNDING: This study was funded by Emory University, the NIH, and the Yerkes National Primate Center.
Authors: Henry M Blumberg; William J Burman; Richard E Chaisson; Charles L Daley; Sue C Etkind; Lloyd N Friedman; Paula Fujiwara; Malgosia Grzemska; Philip C Hopewell; Michael D Iseman; Robert M Jasmer; Venkatarama Koppaka; Richard I Menzies; Richard J O'Brien; Randall R Reves; Lee B Reichman; Patricia M Simone; Jeffrey R Starke; Andrew A Vernon Journal: Am J Respir Crit Care Med Date: 2003-02-15 Impact factor: 21.405
Authors: Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: H N Ho; L E Hultin; R T Mitsuyasu; J L Matud; M A Hausner; D Bockstoce; C C Chou; S O'Rourke; J M Taylor; J V Giorgi Journal: J Immunol Date: 1993-04-01 Impact factor: 5.422
Authors: Clifton E Barry; Helena I Boshoff; Véronique Dartois; Thomas Dick; Sabine Ehrt; JoAnne Flynn; Dirk Schnappinger; Robert J Wilkinson; Douglas Young Journal: Nat Rev Microbiol Date: 2009-10-26 Impact factor: 60.633
Authors: R Brad Jones; Lishomwa C Ndhlovu; Jason D Barbour; Prameet M Sheth; Aashish R Jha; Brian R Long; Jessica C Wong; Malathy Satkunarajah; Marc Schweneker; Joan M Chapman; Gabor Gyenes; Bahareh Vali; Martin D Hyrcza; Feng Yun Yue; Colin Kovacs; Aref Sassi; Mona Loutfy; Roberta Halpenny; Desmond Persad; Gerald Spotts; Frederick M Hecht; Tae-Wook Chun; Joseph M McCune; Rupert Kaul; James M Rini; Douglas F Nixon; Mario A Ostrowski Journal: J Exp Med Date: 2008-11-10 Impact factor: 14.307
Authors: Uma Shanmugasundaram; Allison N Bucsan; Shashank R Ganatra; Chris Ibegbu; Melanie Quezada; Robert V Blair; Xavier Alvarez; Vijayakumar Velu; Deepak Kaushal; Jyothi Rengarajan Journal: JCI Insight Date: 2020-07-23
Authors: Chang Liu; Zhen Zhao; Jia Fan; Christopher J Lyon; Hung-Jen Wu; Dobrin Nedelkov; Adrian M Zelazny; Kenneth N Olivier; Lisa H Cazares; Steven M Holland; Edward A Graviss; Ye Hu Journal: Proc Natl Acad Sci U S A Date: 2017-03-27 Impact factor: 11.205
Authors: Chunxin Liao; Jiahui Yang; Jinli Wang; Xialin Du; Ruining Wang; Shimeng Zhang; Wenting He; Qian Wen; Li Ma Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2018-01-30
Authors: Charlotte A James; Krystle K Q Yu; Martine Gilleron; Jacques Prandi; Vijayendar R Yedulla; Zuzanna Z Moleda; Eleonora Diamanti; Momin Khan; Varinder K Aggarwal; Josephine F Reijneveld; Peter Reinink; Stefanie Lenz; Ryan O Emerson; Thomas J Scriba; Michael N T Souter; Dale I Godfrey; Daniel G Pellicci; D Branch Moody; Adriaan J Minnaard; Chetan Seshadri; Ildiko Van Rhijn Journal: Cell Chem Biol Date: 2018-02-01 Impact factor: 8.116
Authors: Patricia S Grace; Sepideh Dolatshahi; Lenette L Lu; Adam Cain; Fabrizio Palmieri; Linda Petrone; Sarah M Fortune; Tom H M Ottenhoff; Douglas A Lauffenburger; Delia Goletti; Simone A Joosten; Galit Alter Journal: Front Immunol Date: 2021-07-05 Impact factor: 7.561